



Altimune to Participate at Two Upcoming Investor Conferences

November 26, 2024 at 7:30 AM EST

GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:

- **Annual Evercore HealthCONx Conference** (Coral Gables, FL)
Tuesday, December 3, 2024
Fireside Chat at 10:50 a.m. Eastern Time
- **Piper Sandler Annual Healthcare Conference** (New York, NY)
Wednesday, December 4, 2024
Fireside Chat at 3:30 p.m. Eastern Time

The sessions will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [Twitter](#)

Company Contact:

Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contact:

Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Media Contact:

Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc